Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia in clinical practice. The risk of developing AF increases with age and tends to be higher in males than in females. The disease presents a wide spectrum of symptoms and severity AND it is progressive. Its current global prevalence is around 34 million patients, which is expected to increase as the general population ages. Paroxysmal AF accounts for approximately 39% of all diagnosed prevalent cases of AF.
InRhythm, our lead product under development, is an inhaled therapy to treat symptomatic paroxysmal atrial fibrillation (PAF) using approved drugs via inhalation.
Atrial fibrillation involves the two upper chambers (atria) of the heart. Its name comes from the fibrillating (i.e. quivering) of the heart muscles of the atria instead of a coordinated contraction.
Paroxysmal atrial fibrillation (PAF) is a type of AF where episodes terminate spontaneously in less than 7 days, usually in less than 24 hours. About 1 in 4 people with paroxysmal atrial fibrillation eventually develop the permanent form of the condition.
The causes of PAF aren’t always known. They can be similar to causes of chronic AF, although most people with PAF have normal hearts. People with PAF appear to be at just as high a risk of developing blood clots as those with chronic AF.
Common symptoms of PAF can include:
Atrial fibrillation remains a significant unmet medical need. Current therapeutic and interventional options are inadequate and the incidence of AF is projected to grow significantly over the coming years. It is currently treated either through pharmacological intervention with a combination of rhythm control, rate control and anticoagulation therapies; electrical cardioversion; and/or catheter ablation. PAF results in high direct and indirect costs including physician visits, ER visits and extended hospital stays, in addition to costs related to complications as a result of invasive procedures.